Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Calcitriol vs. Paricalcitol for Mineral and Bone Disease in Hemodialysis (ECRIP)
NCT01725113Phase 4Terminated
- Sponsor
- NYU Langone Hospital – Long Island
- Start
- Nov 2012
- Primary completion
- Dec 2013
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of calcitriol and paricalcitol in secondary hyperparathyroidism (SHPT) and chronic kidney disease-mineral and bone disorder (CKD-MBD), sponsored by NYU Langone Hospital – Long Island. Primary endpoint: Calcium Levels at Month 3 Post Calcitriol Treatment Initiation. Started Nov 2012; status: terminated.
02
Drugs
calcitriolparicalcitol
03
Conditions
secondary hyperparathyroidism (SHPT)chronic kidney disease-mineral and bone disorder (CKD-MBD)
Beyond the preview
Go deeper on NCT01725113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01725113.